Study explores effect of hereditary cancer risk assessments on families of patients with prostate cancer
“This is one of the first large-scale, and by that, I mean a national-based study throughout the United States, with geographical diversity of community-based urology practices that had a pretty sophisticated background of advanced prostate cancer care,” says Neal D. Shore, MD, FACS.
In this video, Neal D. Shore, MD, FACS, discusses the background and methods of the study, “Hereditary cancer risk assessment in the community urology practice setting,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Grant to fund research on biomarkers for toxicity from prostate cancer radiation
July 11th 2024“By understanding the mirSNP genetic markers that predispose patients to adverse side effects from cancer therapy we can tailor these therapies to minimize harm and maximize efficacy," says Joanne B. Weidhaas, MD, PhD, MS.
Gene-expression signature could serve as biomarker for recurrence in ccRCC
June 26th 2024“Even when we adjusted for other clinical variables, like age or grade of tumor, this signature was still independently associated with recurrence after treatment for this form of kidney cancer," says Simpa S. Salami, MD, MPH.
